ChiCTR1900023572 版本V1.0 版本创建时间2019/07/27 16:34:31 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900023572 

最近更新日期:

Date of Last Refreshed on:

2019-06-02 14:49:48 

注册时间:

Date of Registration:

2019-06-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

方佳医师:该研究尚未获得伦理委员会批准。请于批准后再开始纳入参试者,并与我们联系上传批件。 基于荧光蛋白的探针检测临床生物样本代谢物水平

Public title:

Fluorescent protein-based detection of metabolites in clinical specimens

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于荧光蛋白的探针检测临床生物样本代谢物水平

Scientific title:

Fluorescent protein-based detection of metabolites in clinical specimens

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

方佳 

研究负责人:

时海波 

Applicant:

Jia Fang 

Study leader:

Haibo Shi 

申请注册联系人电话:

Applicant telephone:

+86 15800605787

研究负责人电话:

Study leader's telephone:

+86 021-24058706

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

fangjia2008@sjtu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

haibo99@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市宜山路600号

研究负责人通讯地址:

上海市宜山路600号

Applicant address:

600 Yishan Road, Shanghai

Study leader's address:

600 Yishan Road, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学附属第六人民医院

Applicant's institution:

Shanghai Jiaotong University Affiliated Sixth People’s Hospital

研究负责人所在单位:

上海交通大学附属第六人民医院

Affiliation of the Leader:

Shanghai Jiaotong University Affiliated Sixth People’s Hospital

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市宜山路600号

Primary sponsor:

600 Yishan Road, Shanghai

研究实施负责(组长)单位地址:

上海交通大学附属第六人民医院

Primary sponsor's address:

Shanghai Jiaotong University Affiliated Sixth People’s Hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学附属第六人民医院

具体地址:

宜山路600号

Institution
hospital:

Shanghai Jiaotong University Affiliated Sixth People’s Hospital

Address:

600 Yishan Road

经费或物资来源:

国家自然科学基金委

Source(s) of funding:

National natural science foundation of China

Target disease:

Nervous system disease/sudden deafness/acoustic neuroma/suppurative otitis media

Target disease code:

研究类型:

基础科学研究

Study type:

Basic Science

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

本研究的目的是发现疾病生物标记物,为临床疾病的早期诊断提供新的思路,同时期望为其治疗提供新的药物研发方向。  

Objectives of Study:

The purpose of this study is to discover disease biomarkers, provide new ideas for early diagnosis of clinical diseases, and provide new drug development direction for treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)临床住院患者进行腰椎穿刺及脑脊液检查者;
(2)临床住院/门诊患者进行血液生化检查者;
(3)临床住院/门诊患者进行尿液生化检查者。

Inclusion criteria

(1) patients who underwent lumbar puncture and cerebrospinal fluid examination;
(2) blood biochemical examination for clinical inpatients/outpatients;
(3) inpatient/out-patient urine biochemical examination.

排除标准:

(1)可疑颅高压、脑疝;
(2)可疑颅内占位病变;
(3)休克等危重病人;
(4)有严重的凝血功能障碍患者,如血友病患者等除外。

Exclusion criteria:

(1) suspected cranial hypertension and cerebral hernia;
(2) suspected intracranial space-occupying lesions;
(3) shock and other critical patients;
(4) patients with severe coagulation dysfunction, such as hemophiliacs, are excluded.

研究实施时间:

Study execute time:

From 2019-07-01 00:00:00 To 2022-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-07-01 00:00:00 To 2021-08-01 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

120

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

no intervention

Intervention code:

组别:

试验组

样本量:

280

Group:

experimental group

Sample size:

干预措施:

干预措施代码:

Intervention:

no intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海交通大学附属第六人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Jiaotong University Affiliated Sixth People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

未结合胆红素

指标类型:

主要指标

Outcome:

unconjugated bilirubin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

代谢物

指标类型:

主要指标

Outcome:

metabolite

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

脑脊液

组织:

Sample Name:

Cerebrospinal fluid

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

百度云盘

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Baidu cloud disk

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.病例记录表 2.电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1.Case Record Form, CRF 2.Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-06-02 14:49:48